Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Atorvastatin
Regeneron UK Limited
Hypercholesterolemia
1 trial -
CMP-001
Regeneron UK Limited
Melanoma
3 trials -
Cemdisiran
Regeneron UK Limited
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
Cemiplimab
Regeneron UK Limited
Squamous Cell Carcinoma (SCC)
1 trial -
Cemiplimab
Regeneron UK Limited
Recurrent Lung Non-Small Cell Carcinoma
1 trial -
Cemiplimab
Regeneron UK Limited
Cutaneous Squamous Cell Carcinoma
7 trials -
Cemiplimab
Regeneron UK Limited
Cutaneous Squamous Cell Carcinoma (CSCC)
1 trial -
Dupilumab
Regeneron UK Limited
Wheezing
1 trial -
Dupilumab
Regeneron UK Limited
Prurigo Nodularis
1 trial -
Dupilumab
Regeneron UK Limited
Lichen Simplex Chronicus
2 trials -
Dupilumab
Regeneron UK Limited
Eosinophilic Esophagitis (EoE)
2 trials -
Dupilumab Prefilled Syringe
Regeneron UK Limited
Asthma Control
1 trial -
Dupilumab SAR231893
Regeneron UK Limited
Cold Urticaria
1 trial -
Dupilumab SAR231893
Regeneron UK Limited
Allergic Fungal Rhinosinusitis
1 trial -
Dupilumab SAR231893
Regeneron UK Limited
Neurodermatitis
2 trials -
Dupilumab SAR231893
Regeneron UK Limited
Chronic Obstructive Pulmonary Disease
2 trials -
Dupilumab SAR231893
Regeneron UK Limited
Asthma
1 trial -
Dupilumab SAR231893
Regeneron UK Limited
Chronic Rhinosinusitis Without Nasal Polyps
1 trial -
Dupilumab SAR231893
Regeneron UK Limited
Chronic Spontaneous Urticaria
1 trial -
Dupilumab SAR231893 (REGN668)
Regeneron UK Limited
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
2 trials -
Dupilumab SAR231893 (REGN668)
Regeneron UK Limited
Asthma
2 trials -
Eylea (Aflibercept, BAY86-5321)
Regeneron UK Limited
Retinopathy of Prematurity (ROP)
2 trials -
Fasinumab
Regeneron UK Limited
Chronic Low Back Pain
1 trial -
Fasinumab
Regeneron UK Limited
Low Back Pain
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources